NICE decision regarding brexucabtagene autoleucel for mantle cell lymphoma
NICE has announced that it will reconsider its decision to recommend the removal of brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma.
News
New treatments and drug approvals
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
NICE recommends lisocabtagene maraleucel for large B-cell lymphoma
An additional CAR-T cell therapy is available to treat relapsed or refractory large B-cell lymphoma.
New treatments available for CLL
Acalabrutinib has been approved for use by the SMC, and pirtobrutinib has been recommended for use by NICE.
NICE guidance for lymphoma treatments
NICE recommends epcoritamab for the treatment of follicular lymphoma, but not acalabrutinib for mantle cell lymphoma.
New treatment for CLL recommended by NICE
NICE has approved venetoclax with obinutuzumab for people with untreated chronic lymphocytic leukaemia.
NICE recommends new treatment for DLBCL
GlofitGemOx now available for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Shingles vaccine open to thousands more
People over the age of 18 with a severely weakened immune system are now able to have the shingles vaccination.
Two lymphoma treatments approved for use in Scotland
SMC recommends new treatment options for mantle cell lymphoma and Hodgkin lymphoma.
New treatment available for mantle cell lymphoma
The treatment zanubrutinib has been approved by NICE for relapsed or refractory mantle cell lymphoma.
New treatment for Hodgkin lymphoma recommended by NICE
NICE has approved brentuximab vedotin for people with untreated stage 3 or 4 CD30-positive Hodgkin lymphoma.